Surface Oncology, Inc. (SURF)
(Delayed Data from NSDQ)
$4.87 USD
+0.02 (0.41%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.87 USD
+0.02 (0.41%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Small Caps Post Best Recovery From September Mayhem: 7 Picks
by Nalak Das
The small-cap stocks have outperformed their large-cap peers in the market's turnaround from the September turmoil.
Surface Oncology's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Surface Oncology.
Zacks.com featured highlights include: Fulgent Genetics, Primoris Services, Niu Technologies, Surface Oncology and Aldeyra Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: Fulgent Genetics, Primoris Services, Niu Technologies, Surface Oncology and Aldeyra Therapeutics
5 Stocks to Buy as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Surface Oncology (SURF) Looks Good: Stock Adds 9.8% in Session
by Zacks Equity Research
Surface Oncology (SURF) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Abbott (ABT) Looks Good: Stock Adds 7.9% in Session
by Zacks Equity Research
Abbott (ABT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Surface Oncology Inc (SURF) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Surface Oncology Inc (SURF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Surface Oncology (SURF) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SURF) Outperforming Other Medical Stocks This Year?
Surface Oncology, Inc. (SURF) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Surface Oncology, Inc. (SURF).
Company News For Nov 26, 2019
by Zacks Equity Research
Companies In The News Are:
Surface Oncology, Inc. (SURF) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -5.17% and -86.24%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Surface Oncology, Inc. (SURF) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -3.23% and -94.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Surface Oncology, Inc. (SURF) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Surface Oncology, Inc. (SURF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Surface Oncology, Inc. (SURF) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of 65.91% and 477.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?